Salvage resection for recurrent or metastatic hepatocellular carcinoma after percutaneous ablation therapy

Int J Surg. 2016 Dec;36(Pt A):68-73. doi: 10.1016/j.ijsu.2016.07.066. Epub 2016 Jul 29.

Abstract

Introduction: To retrospectively evaluate the efficacy and safety of salvage resection(SR) for recurrence or metastasis of hepatocellular carcinoma (HCC) after initial percutaneous ablation therapy (PAT).

Methods: From September 2006 to September 2013, 50 consecutive patients who received SR for recurrent or metastatic HCC undergone initial PAT were enrolled. Safety and efficacy of SR for these patients were analyzed.

Results: No treatment-related death occurred. Curative outcome was achieved in all the patients. The median overall survival after SR was 40 months, and the 1-, 3-, 5-year overall survival rate after SR was 85.2%, 46.4% and 34.8%, respectively. The disease-free survival was 38.6% at 1 year and 12.1% at 3 years after SR.

Conclusion: SR is an effective and safe method for patients with recurrent or metastatic HCC after initial PAT treatment.

Keywords: Percutaneous ablation therapy; Recurrent or metastatic HCC; Salvage resection.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / surgery*
  • Catheter Ablation / adverse effects
  • Catheter Ablation / methods*
  • Female
  • Follow-Up Studies
  • Hepatectomy / adverse effects
  • Hepatectomy / methods*
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / surgery
  • Retrospective Studies
  • Salvage Therapy / adverse effects
  • Salvage Therapy / methods*
  • Salvage Therapy / mortality
  • Survival Rate
  • Treatment Outcome